Edwards Lifesciences’ transcatheter aortic valve replacement (TAVR) system has demonstrated positive results in a long-term trial readout, as global demand for the technology increases. The company ...

SAN FRANCISCO--(BUSINESS WIRE)-- Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The ...

Price targets for Edwards Lifesciences are clustering in the mid to high US$90s and above US$100, while one model holds fair ...

Add Yahoo as a preferred source to see more of our stories on Google. Edwards Lifesciences' Sapien 3 Ultra system. The artificial heart valve is pushed through the blood vessels via a catheter and ...

Concerns of hemolysis continued to swirl around the Sapien 3 Ultra Resilia, with yet another report indicating such harm after transcatheter aortic valve replacement (TAVR). In a single-center ...

Six-year follow-up from a trial comparing surgery with TAVR in low-risk patients showed no difference in major events, but the reintervention was higher in the TAVR arm.

The Structural Heart Program team at McGovern Medical School at The University of Texas Health Science Center at Houston (UTHealth) is among the first in the country to investigate the safety and ...

“We are pleased to report strong second quarter results that delivered double-digit sales growth. Based on our better-than-expected first half performance and the many catalysts across our portfolio, ...

Edwards Lifesciences EW has delivered an impressive return over the past year, with shares rallying 22.1%. The stock comfortably outpaced the industry’s 3.8% fall and closely tracked the S&P 500 ...

SAPIEN 3, which showed superiority at 1 year, also demonstrates compelling outcomes equivalent to surgery at seven years SAN FRANCISCO--(BUSINESS WIRE)-- Edwards Lifesciences (EW) today announced ...